Ieq Capital LLC Has $7.25 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Ieq Capital LLC reduced its holdings in Pfizer by 10.7%, owning 286,120 shares valued at $7.25 million after selling 34,352 shares.
• Pfizer recently announced a quarterly dividend of $0.43 per share, yielding approximately 7.0% annually, with a payout ratio of 91.49%.
• Analysts provide a consensus rating of "Hold" for Pfizer, with target prices ranging from $26.00 to $33.00, indicating a mixed outlook on the stock's performance.

Ieq Capital LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 286,120 shares of the biopharmaceutical company's stock after selling 34,352 shares during the quarter. Ieq Capital LLC's holdings in Pfizer were worth $7,250,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PFE. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after buying an additional 2,087 shares in the last quarter. Voleon Capital Management LP acquired a new position in Pfizer during the 4th quarter worth $2,120,000. Kapitalo Investimentos Ltda bought a new stake in shares of Pfizer during the 4th quarter valued at $89,000. Finally, Triumph Capital Management raised its position in shares of Pfizer by 20.0% during the 4th quarter. Triumph Capital Management now owns 10,283 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 1,717 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on PFE. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Jefferies Financial Group upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Finally, HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Price Performance

PFE opened at $24.60 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a fifty day simple moving average of $24.78 and a 200 day simple moving average of $24.39. The stock has a market cap of $139.86 billion, a P/E ratio of 13.09, a P/E/G ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the prior year, the company earned $0.60 EPS. The firm's quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.